• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性冠状动脉综合征患者中,共抑制分子程序性死亡配体1(PD-L1)在CD4⁺CD25⁺FOXP3⁺调节性T细胞上的表达升高。

Expression of coinhibitory PD-L1 on CD4⁺CD25⁺FOXP3⁺ regulatory T cells is elevated in patients with acute coronary syndrome.

作者信息

Li Si-Hui, Chen Wei-Jun, Yan Min, Shu Yan-Wen, Liao Yu-Hua

机构信息

Department of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

出版信息

Coron Artery Dis. 2015 Nov;26(7):598-603. doi: 10.1097/MCA.0000000000000282.

DOI:10.1097/MCA.0000000000000282
PMID:26166019
Abstract

OBJECTIVE

Coronary heart disease (CHD) is associated with high morbidity and mortality worldwide. CD4⁺CD25⁺FOXP3⁺ regulatory T cells (Tregs) play a role in the modulation of vascular inflammation. The negatively costimulatory molecule programmed cell death ligand 1 (PD-L1) exerts a prominent effect on the adjustment of immune responses. We investigated the relationship between the expression of PD-L1 on peripheral blood Tregs and the severity of CHD.

METHODS AND RESULTS

Human peripheral blood was collected from 59 patients with CHD and 11 healthy volunteers. The expression of PD-L1 on peripheral blood Tregs was detected by flow cytometry, and the production of interleukin 2 (IL-2), IL-4, IL-10, and transforming growth factor β1 in plasma was determined using enzyme-linked immunosorbent assay. The subgroup of patients with acute coronary syndrome (ACS), which includes unstable angina pectoris, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction, showed a significant reduction of FOXP3 and PD-L1 expression on Tregs compared with the subgroup of patients with chronic coronary artery disease, comprising stable angina pectoris, silent myocardial ischemia, and ischemic heart failure, and the control group. Moreover, the ACS group showed significantly increased production of IL-2, and decreased production of IL-4, IL-10, and transforming growth factor β1, compared with the coronary artery disease and control groups.

CONCLUSION

Expression of the coinhibitory molecule PD-L1 on peripheral blood Tregs is correlated negatively with the severity of CHD and could serve as a novel indicator of ACS.

摘要

目的

冠心病(CHD)在全球范围内具有高发病率和死亡率。CD4⁺CD25⁺FOXP3⁺调节性T细胞(Tregs)在调节血管炎症中发挥作用。负性共刺激分子程序性细胞死亡配体1(PD-L1)对免疫反应的调节具有显著影响。我们研究了外周血Tregs上PD-L1的表达与CHD严重程度之间的关系。

方法与结果

从59例冠心病患者和11名健康志愿者中采集人外周血。采用流式细胞术检测外周血Tregs上PD-L1的表达,并用酶联免疫吸附测定法测定血浆中白细胞介素2(IL-2)、IL-4、IL-10和转化生长因子β1的产生。急性冠状动脉综合征(ACS)亚组包括不稳定型心绞痛、非ST段抬高型心肌梗死和ST段抬高型心肌梗死,与慢性冠状动脉疾病亚组(包括稳定型心绞痛、无症状心肌缺血和缺血性心力衰竭)及对照组相比,其Tregs上FOXP3和PD-L1的表达显著降低。此外,与冠状动脉疾病组和对照组相比,ACS组IL-2的产生显著增加,而IL-4、IL-10和转化生长因子β1的产生减少。

结论

外周血Tregs上共抑制分子PD-L1的表达与CHD严重程度呈负相关,可作为ACS的一种新指标。

相似文献

1
Expression of coinhibitory PD-L1 on CD4⁺CD25⁺FOXP3⁺ regulatory T cells is elevated in patients with acute coronary syndrome.急性冠状动脉综合征患者中,共抑制分子程序性死亡配体1(PD-L1)在CD4⁺CD25⁺FOXP3⁺调节性T细胞上的表达升高。
Coron Artery Dis. 2015 Nov;26(7):598-603. doi: 10.1097/MCA.0000000000000282.
2
FOXP3 demethylation as a means of identifying quantitative defects in regulatory T cells in acute coronary syndrome.FOXP3 去甲基化作为鉴定急性冠脉综合征中调节性 T 细胞数量缺陷的一种方法。
Atherosclerosis. 2013 Jul;229(1):263-70. doi: 10.1016/j.atherosclerosis.2013.05.007. Epub 2013 May 16.
3
[Changes of Foxp3(+); regulatory T cells in patients with acute coronary syndrome].[急性冠状动脉综合征患者中Foxp3(+)调节性T细胞的变化]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Aug;27(8):893-5.
4
The Th17/Treg imbalance in patients with acute coronary syndrome.急性冠状动脉综合征患者的Th17/Treg失衡
Clin Immunol. 2008 Apr;127(1):89-97. doi: 10.1016/j.clim.2008.01.009. Epub 2008 Feb 21.
5
Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1.人脐静脉内皮细胞通过程序性死亡配体1(PD-L1)促进CD4(+)CD25(+)Foxp3(+)调节性T细胞的抑制性活化。
Atherosclerosis. 2016 Jan;244:108-12. doi: 10.1016/j.atherosclerosis.2015.11.002. Epub 2015 Nov 6.
6
Heme oxygenase-1 restores impaired GARPCD4⁺CD25⁺ regulatory T cells from patients with acute coronary syndrome by upregulating LAP and GARP expression on activated T lymphocytes.血红素加氧酶-1通过上调活化T淋巴细胞上的LAP和GARP表达,恢复急性冠脉综合征患者受损的GARP⁺CD4⁺CD25⁺调节性T细胞。
Cell Physiol Biochem. 2015;35(2):553-70. doi: 10.1159/000369719. Epub 2015 Jan 27.
7
Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease.冠心病患者促炎细胞因子的循环水平及中性粒细胞 - 血小板聚集体
Am J Cardiol. 2005 Feb 15;95(4):452-6. doi: 10.1016/j.amjcard.2004.10.009.
8
Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis.循环 CD4+CD25hiCD127lo 调节性 T 细胞水平不能反映颈动脉和冠状动脉粥样硬化的程度和严重程度。
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1832-41. doi: 10.1161/ATVBAHA.110.206813. Epub 2010 Jun 10.
9
Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome.Th17/Th1 的激活与急性冠状动脉综合征患者的急性心脏事件有关,但不是 Th17。
Atherosclerosis. 2011 Aug;217(2):518-24. doi: 10.1016/j.atherosclerosis.2011.03.043. Epub 2011 Apr 9.
10
Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation.急性冠状动脉综合征患者的循环单核细胞在脂多糖刺激后缺乏足够的白细胞介素-10生成。
Clin Exp Immunol. 2004 Nov;138(2):364-8. doi: 10.1111/j.1365-2249.2004.02602.x.

引用本文的文献

1
Immunophenotyping identifies key immune biomarkers for coronary artery disease through machine learning.免疫表型分析通过机器学习识别冠状动脉疾病的关键免疫生物标志物。
PLoS One. 2025 Aug 26;20(8):e0328811. doi: 10.1371/journal.pone.0328811. eCollection 2025.
2
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure.免疫检查点蛋白PD-1和CTLA-4在导致心力衰竭的心血管并发症中的作用。
Front Immunol. 2025 Apr 4;16:1561968. doi: 10.3389/fimmu.2025.1561968. eCollection 2025.
3
PD-1/PD-L1 and coronary heart disease: a mendelian randomization study.
PD-1/PD-L1与冠心病:一项孟德尔随机化研究
Front Cardiovasc Med. 2024 Oct 18;11:1424770. doi: 10.3389/fcvm.2024.1424770. eCollection 2024.
4
Expression and Significance of Programmed Death-1 and Its Ligands in the Accelerated Formation of Atherosclerosis in an Induced Murine Lupus Model.程序性死亡蛋白-1及其配体在诱导性小鼠狼疮模型动脉粥样硬化加速形成中的表达及意义
Biomed Res Int. 2022 Nov 16;2022:6255383. doi: 10.1155/2022/6255383. eCollection 2022.
5
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.免疫检查点抑制剂相关的心血管免疫相关不良事件。
Front Immunol. 2024 Feb 5;15:1340373. doi: 10.3389/fimmu.2024.1340373. eCollection 2024.
6
Impact of Immunity on Coronary Artery Disease: An Updated Pathogenic Interplay and Potential Therapeutic Strategies.免疫对冠状动脉疾病的影响:最新的致病相互作用及潜在治疗策略
Life (Basel). 2023 Oct 27;13(11):2128. doi: 10.3390/life13112128.
7
Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study.癌症患者中免疫检查点抑制剂治疗与动脉血栓栓塞事件的关联:一项回顾性队列研究。
Cancer Med. 2023 Sep;12(18):18531-18541. doi: 10.1002/cam4.6455. Epub 2023 Aug 16.
8
An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors.对动脉粥样硬化与免疫检查点抑制剂相关性的深入理解。
Curr Cardiol Rep. 2023 Aug;25(8):879-887. doi: 10.1007/s11886-023-01908-4. Epub 2023 Jul 3.
9
Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: State-of-the-Art Review.免疫检查点抑制剂治疗相关动脉粥样硬化:证据、诊断与管理:最新综述
JACC CardioOncol. 2022 Dec 20;4(5):598-615. doi: 10.1016/j.jaccao.2022.11.011. eCollection 2022 Dec.
10
Divergent roles of PD-L1 in immune regulation during ischemia-reperfusion injury.PD-L1 在缺血再灌注损伤中的免疫调节中的分歧作用。
Front Immunol. 2022 Nov 21;13:1021452. doi: 10.3389/fimmu.2022.1021452. eCollection 2022.